Your browser doesn't support javascript.
loading
Human NLRC4 expression promotes cancer survival and associates with type I interferon signaling and immune infiltration.
Domblides, Charlotte; Crampton, Steven; Liu, Hong; Bartleson, Juliet M; Nguyen, Annie; Champagne, Claudia; Landy, Emily E; Spiker, Lindsey; Proffitt, Christopher; Bhattarai, Sunil; Grawe, Anissa P; Fuentealba Valenzuela, Matias; Lartigue, Lydia; Mahouche, Isabelle; Dupaul-Chicoine, Jeremy; Nishimura, Kazuho; Lefort, Félix; Decraecker, Marie; Velasco, Valérie; Netzer, Sonia; Pitard, Vincent; Roy, Christian; Soubeyran, Isabelle; Racine, Victor; Blanco, Patrick; Déchanet-Merville, Julie; Saleh, Maya; Canna, Scott W; Furman, David; Faustin, Benjamin.
Afiliação
  • Domblides C; University of Bordeaux, Bordeaux, France.
  • Crampton S; ImmunoConcEpt, CNRS UMR 5164, INSERM ERL 1303, Bordeaux University, Bordeaux, France.
  • Liu H; Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France.
  • Bartleson JM; Discovery Immunology, Johnson & Johnson Innovative Medicine, San Diego, California, USA.
  • Nguyen A; GI and Immune-Oncology DDUs, Takeda Pharmaceuticals, San Diego, California, and Cambridge, Massachusetts, USA.
  • Champagne C; Buck Institute for Research on Aging, Novato, California, USA.
  • Landy EE; Discovery Immunology, Johnson & Johnson Innovative Medicine, San Diego, California, USA.
  • Spiker L; Department of Medicine, McGill University, Montreal, Québec, Canada.
  • Proffitt C; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Bhattarai S; Department of Genetics, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
  • Grawe AP; GI and Immune-Oncology DDUs, Takeda Pharmaceuticals, San Diego, California, and Cambridge, Massachusetts, USA.
  • Fuentealba Valenzuela M; Discovery Immunology, Johnson & Johnson Innovative Medicine, San Diego, California, USA.
  • Lartigue L; Buck Institute for Research on Aging, Novato, California, USA.
  • Mahouche I; Buck Institute for Research on Aging, Novato, California, USA.
  • Dupaul-Chicoine J; INSERM, U1218 ACTION, F-33000, Bordeaux, France.
  • Nishimura K; INSERM, U1218 ACTION, F-33000, Bordeaux, France.
  • Lefort F; Department of Medicine, McGill University, Montreal, Québec, Canada.
  • Decraecker M; GI and Immune-Oncology DDUs, Takeda Pharmaceuticals, San Diego, California, and Cambridge, Massachusetts, USA.
  • Velasco V; ImmunoConcEpt, CNRS UMR 5164, INSERM ERL 1303, Bordeaux University, Bordeaux, France.
  • Netzer S; Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France.
  • Pitard V; ImmunoConcEpt, CNRS UMR 5164, INSERM ERL 1303, Bordeaux University, Bordeaux, France.
  • Roy C; Comprehensive Cancer Center, Department of Biopathology, Institut Bergonié, Bordeaux, France.
  • Soubeyran I; University of Bordeaux, Bordeaux, France.
  • Racine V; ImmunoConcEpt, CNRS UMR 5164, INSERM ERL 1303, Bordeaux University, Bordeaux, France.
  • Blanco P; University of Bordeaux, Bordeaux, France.
  • Déchanet-Merville J; ImmunoConcEpt, CNRS UMR 5164, INSERM ERL 1303, Bordeaux University, Bordeaux, France.
  • Saleh M; GI and Immune-Oncology DDUs, Takeda Pharmaceuticals, San Diego, California, and Cambridge, Massachusetts, USA.
  • Canna SW; Comprehensive Cancer Center, Department of Biopathology, Institut Bergonié, Bordeaux, France.
  • Furman D; QuantaCell, Hôpital Saint Eloi, IRMB, Montpellier, France.
  • Faustin B; University of Bordeaux, Bordeaux, France.
J Clin Invest ; 134(11)2024 Apr 23.
Article em En | MEDLINE | ID: mdl-38652550
ABSTRACT
The immune system can control cancer progression. However, even though some innate immune sensors of cellular stress are expressed intrinsically in epithelial cells, their potential role in cancer aggressiveness and subsequent overall survival in humans is mainly unknown. Here, we show that nucleotide-binding oligomerization domain-like receptor (NLR) family CARD domain-containing 4 (NLRC4) is downregulated in epithelial tumor cells of patients with colorectal cancer (CRC) by using spatial tissue imaging. Strikingly, only the loss of tumor NLRC4, but not stromal NLRC4, was associated with poor immune infiltration (mainly DCs and CD4+ and CD8+ T cells) and accurately predicted progression to metastatic stage IV and decrease in overall survival. By combining multiomics approaches, we show that restoring NLRC4 expression in human CRC cells triggered a broad inflammasome-independent immune reprogramming consisting of type I interferon (IFN) signaling genes and the release of chemokines and myeloid growth factors involved in the tumor infiltration and activation of DCs and T cells. Consistently, such reprogramming in cancer cells was sufficient to directly induce maturation of human DCs toward a Th1 antitumor immune response through IL-12 production in vitro. In multiple human carcinomas (colorectal, lung, and skin), we confirmed that NLRC4 expression in patient tumors was strongly associated with type I IFN genes, immune infiltrates, and high microsatellite instability. Thus, we shed light on the epithelial innate immune sensor NLRC4 as a therapeutic target to promote an efficient antitumor immune response against the aggressiveness of various carcinomas.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas de Ligação ao Cálcio / Neoplasias Colorretais / Transdução de Sinais / Interferon Tipo I / Regulação Neoplásica da Expressão Gênica / Proteínas Adaptadoras de Sinalização CARD Limite: Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas de Ligação ao Cálcio / Neoplasias Colorretais / Transdução de Sinais / Interferon Tipo I / Regulação Neoplásica da Expressão Gênica / Proteínas Adaptadoras de Sinalização CARD Limite: Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article